Luan SX, et al. - An inquiry was set up with regard to the efficacy, acceptability, safety and quality of life of adjunctive aripiprazole in patients with treatment-resistant depression (TRD). Benefits in improving the response rate, remission rate, and the quality of life were gained in patients with TRD due to adjunctive aripiprazole. Owing to the evidence of potential treatment-related side effects cautious interpretation of these findings was recommended.